Enanta Pharmaceuticals Inc

Chart & Performance

D1W1MN

P/E

—

P/S

4.84

EPS

—

Div Yield, %

—

Shrs. gr., 5y

0.18%

Rev. gr., 5y

-19.91%

Revenues

68m

-14.61%

Net income

-116m

L-13.28%

CFO

-79m

L-23.64%

Earnings

May 11, 2026

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

URL

https://www.enanta.com/

IPO date

Mar 21, 2013

Employees

160

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2025‑09	2024‑09	2023‑09	2022‑09	2021‑09	2020‑09	2019‑09	2018‑09	2017‑09	2016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT